BERKELEY, US – MAINZ, Germany – March 6th, 2024 — Mainz Biomed N.V. (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, is proud to announce its participation as an exhibitor at the esteemed Gynecology Congress (‘Gynäkologie und Geburtshilfe aktuell’) in Stuttgart, Germany, on March 1st. This engagement signifies the company’s commitment to advancing colorectal cancer (CRC) screening through their innovative diagnostic solution ColoAlert® and highlights the pivotal role of gynecologists in the early detection of this prevalent disease.
In the landscape of CRC prevention, a broad spectrum of healthcare professionals, including gastroenterologists, general practitioners, gynecologists (GYNs), and urologists, play crucial roles, primarily through the administration of Fecal Immunochemical Tests (FIT), the current standard of non-invasive CRC screening, that identifies blood in stool samples. With over 3 million FIT tests conducted in Germany annually, gynecologists stand out as a key group, responsible for 27% of these screenings, second only to general practitioners who conduct 34%. This data underscores the significant impact gynecologists have in the early detection and prevention efforts against CRC.
The Gynecology Congress is a premier event dedicated to gynecological health, offering Mainz Biomed an invaluable opportunity to connect with these vital healthcare providers. The company’s showcase of ColoAlert®, an advanced diagnostic tool that surpasses traditional FIT by detecting not only blood in stool but also tumor DNA, aims to set a new standard in CRC screening. By addressing the limitations of FIT tests, which cannot detect non-bleeding tumors, ColoAlert® offers a more comprehensive screening approach, potentially identifying CRC at earlier stages.
Mainz Biomed’s presence at the congress is part of a broader initiative to build stronger relationships with healthcare professionals who are integral to the company’s laboratory partnerships. This effort is aimed at increasing brand awareness and establishing ColoAlert® as a key component in medical practices for CRC screening.
In the coming months, Mainz Biomed will continue to actively participate in medical conferences that cater to its key demographic. A highlight will be the company’s involvement in the 130th Congress of the German Society for Internal Medicine in April, where Mainz Biomed is expected to contribute significantly through a symposium presentation, further emphasizing its leadership in molecular diagnostics for cancer screening.